- Condition
- Type 2 Diabetes Mellitus
- Patient profile
- M, age band 50–59, Saudi Arabia
- Outcome scale
- HbA1c (lower is better)
Twelve-month HbA1c follow-up of a Saudi Arabian patient with type 2 diabetes treated under a Wharton's Jelly MSC metabolic protocol in Istanbul.
HbA1c response in type 2 diabetes is multifactorial. This case occurred against optimized pharmacotherapy and is not a predictor of any other patient's outcome.
HbA1c timeline
HbA1c reflects average blood glucose over ~90 days. ADA defines <5.7% as normal, 5.7–6.4% as prediabetes, and ≥6.5% as diabetes. A change of ≥0.5% is typically considered clinically meaningful.
| Timepoint | HbA1c | Δ vs baseline |
|---|---|---|
| Baseline | 8.9 | — |
| Day 90 | 7.8 | -1.1 |
| Day 180 | 7.1 | -1.8 |
| Day 365 | 7 | -1.9 |
Type 2 diabetes mellitus, 8 years since diagnosis, on metformin plus a GLP-1 agonist. Baseline HbA1c 8.9% despite optimized lifestyle counseling. BMI 32.4. No microvascular complications documented at baseline.
Intravenous Wharton's Jelly MSCs across two infusions with structured metabolic workup (fasting glucose, HbA1c, fasting insulin, HOMA-IR, lipid panel, hsCRP). All baseline anti-diabetic medications continued in coordination with home endocrinology.
HbA1c re-tested at Days 90, 180 and 365 by the home endocrinologist. Patient reported improved fasting energy and reduced post-prandial somnolence. No medication escalation required.
Mild transient fatigue for 24 hours post infusion. No hypoglycemic episodes.